Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587760 | 0.93 | HTT (0.39) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL14587759 | 0.92 | HTT (0.40) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL5010820 | 0.90 | HTT (0.43) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL14297710 | 0.84 | CYP2C19 (0.41) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL14587752 | 0.84 | HTT (0.41) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL5010646 | 0.83 | CYP2C19 (0.41) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL14587754 | 0.83 | NPC1 (0.39) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL5009816 | 0.83 | HTT (0.43) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL5010563 | 0.83 | HTT (0.41) | HTTRECQLNPC1RAB9AMAPT | |
| SCHEMBL14587645 | 0.82 | NPC1 (0.42) | HTTRECQLNPC1RAB9APYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HTT 4237/4885RECQL 766/4885NPC1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.